Voyageur Pharmaceuticals Ltd. is a Canadian company founded in 2017 by brothers Brent and Brad Willis who have more than 30 years’ experience in the development of mining-based solutions. This led them to explore the wide use of different minerals throughout the world. They realized that products used to enhance medical images relied on very limited supply of raw materials from countries many miles from Canada. As a result, they started work on developing a local supply chain for the medical market.
Voyageur Pharmaceuticals is in the business of acquiring, exploring and developing mineral exploration properties, primarily in the province of British Columbia, Canada and the states of Utah and Oklahoma, United States. The Company is focused on the development of barite and iodine Active Pharmaceutical Ingredients (API) and imaging contrast agents for the medical radiology marketplace. It owns a 100% interest in three barium sulfate (barite) projects. The Company operates through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc. It is focused on developing its barium sulfate project, Frances Creek, in BC, Canada for pharmaceutical barium contrast applications, such as x-radiation, computed tomography scans and magnetic resonance imaging applications. It also owns mineral brine claims in Utah United States.
Voyageur Pharmaceuticals aims to address the shortage of API’s in contrast media and develop new and innovative products to help improve patient diagnosis.
Voyageur Pharmaceuticals is working closely with leading radiologists to build up a portfolio of products designed to ease the work of busy radiology units. Our aim is to provide choices to patients and medical imaging specialists with the assurance of highest quality.
The lack of innovation of barium sulfate contrast media products has resulted in a stagnated market with no new choices available to clinicians. Voyageur Pharmaceuticals exists to bring to the market new and exciting solutions for all contrast media needs.